Scarica l'app Stockscreener
23.07
4.19%
-1.01
Dopo l'orario di chiusura:
23.04
-0.03
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Capricor’s positive 5-year data for DMD treatment comes with a regulatory catch – CAPR stock slides 11% - MSN
July meeting date set for FDA, developer to talk deramiocel for DMD - Muscular Dystrophy News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review - Stocktwits
Securities Class Action Lawsuit Filed Against Capricor Therapeuti - The National Law Review
Capricor CFO Bergmann sells $732k in shares By Investing.com - Investing.com Australia
Capricor Therapeutics EVP Karen Krasney sells $732,158 in stock By Investing.com - Investing.com Australia
Form 4 Capricor Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
Capricor (NASDAQ: CAPR) EVP exercises options and sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor (NASDAQ: CAPR) CFO sells 24,100 shares under 10b5-1 plan - Stock Titan
Capricor Therapeutics Insiders Sold Shares Worth Over $1.5M - TradingView
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell 3000E Index - marketscreener.com
Capricor Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your - The National Law Review
Capricor Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Litvack Frank - Moomoo
Capricor Therapeutics, Inc.(NasdaqGS: CAPR) dropped from Russell Microcap Index - marketscreener.com
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Contact Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi - The National Law Review
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
CAPR Stock Surged 17% Today — What’s Fueling The Rally? - Stocktwits
Capricor falls as FDA sets up AdCom meeting to review Duchenne therapy - MSN
Class Action Alert: Levi & Korsinsky Reminds Capricor (CAPR) Investors of September 15, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) Shar - The National Law Review
CAPR ALERT: Levi & Korsinsky Files Securities Fraud Class Action - The National Law Review
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics Faces Stock Drop Ahead of FDA Advisory Meeting - Intellectia AI
Capricor Therapeutics Announces FDA Advisory Committee Meeting for Deramiocel Cell Therapy in Duchenne Muscular Dystrophy – Minichart - Minichart
Capricor Therapeutics to Face FDA Advisory Panel on BLA for Deramiocel; PDUFA Aug 22 - TradingView
[8-K] CAPRICOR THERAPEUTICS, INC. Reports Material Event - Stock Titan
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
What's Going On With Capricor Therapeutics Stock On Friday? - Benzinga
Capricor Therapeutics (CAPR) Reports Positive Long-Term Data for Deramiocel - GuruFocus
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% - Stocktwits
Capricor Therapeutics, Inc. (CAPR) Stock: July FDA Review Tests Deramiocel Outlook - parameter.io
Capricor Therapeutics (CAPR) Faces 12% Decline Ahead of FDA Advi - GuruFocus
Capricor Therapeutics (CAPR) Seeks FDA Meeting for Cell Therapy Approval - GuruFocus
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout | AI
FDA schedules advisory meeting for Capricor’s DMD therapy By Investing.com - Investing.com India
Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set For August 22 - TradingView
Capricor Therapeutics Announces FDA Advisory Committee - GlobeNewswire
FDA panel to review Capricor’s Duchenne drug on July 29 - Stock Titan
Capricor faces FDA AdCom panel for Duchenne drug (CAPR:NASDAQ) - Seeking Alpha
Capricor reports five-year data for Duchenne therapy deramiocel By Investing.com - Investing.com Canada
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference - The Manila Times
Capricor to Present Positive Five-Year HOPE-2 OLE Data and - GlobeNewswire
Capricor Therapeutics, Inc. Actuals & Estimates (NASDAQ:CAPR) - TradingView
CAPR Forecast — Price Target — Prediction for 2027 - TradingView
A2PLU4 Forecast — Price Target — Prediction for 2027 - TradingView
Capricor EVP, general counsel Karen Krasney sells $27,000 in stock - Investing.com UK
Anthony Bergmann, CFO, sells $27,000 in Capricor Therapeutics stock - Investing.com UK
Capricor Therapeutics Inc (CAPR) Institutional Confidence - TradingKey
Form 4 Capricor Therapeutics Inc For: 24 June By Investing.com - Investing.com Australia
0.93%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):